Does concomitant treatment with cholinesterase inhibitors or memantine affect cerebrolysin treatment's efficacy in Alzheimer disease? Results from the Argentinean cerebrolysin registry

O (donepezil) 21 9 0 30 21.16 1.89 I (rivastigmine) 25 9 2 36 17.42 1.73 A (gallantamine) 9 3 0 12 20.66 2 E (memantine) 14 3 1 18 18.10 0.66 OME 40 1 2 43 18.52 3.75 IME 21 9 1 31 15.85 2.26 AME 5 2 0 7 17.83 3 e (cerebrolysin) 20 4 1 25 19.47 4.68 otal 155 40 7 202 18.54 2.76 Diana Pollock, Vikram Atit, George Brewer, Steven Kanzer, Lara Guzman, David Newsome, Ptak Alzheimer’s Research Center, Clearwater, Florida, United States; Atit Neurology Institute, Holiday, Florida, United States; Adeona, Ann Arbor, Michigan, United States.